Search Results

COVID-19 has impacted how providers are dispensing multiple myeloma medications and providing care to patients during the pandemic. Learn how to identify those effects to help mitigate them and implement strategies to improve telehealth medicine during the pandemic.

Panelists discussed considerations for resuming pre-pandemic level visits and procedures for patients with CLL, AML, and Multiple Myeloma. Hear wins and challenges in providing care in a pandemic.

An expert panel of past ACCC Presidents will share their perspectives on changes to clinical research during the pandemic.

Hear considerations for treating patients with CLL during the pandemic, including best options, treatment timing, changes to the usual regimen, and how to prepare for the future.

Join a panel of Montefiore Health System providers for an in-depth look at their pandemic preparations and response and how they’re collecting data for care coordination and research. (June 19, 2020)

Financial advocacy experts will come together to discuss critical financial advocacy tips that can benefit your patients and your cancer program during the economic crisis resulting from the pandemic. (July 29, 2020)

The pandemic has heightened the distress patients with CLL face and taken its toll on providers. Learn strategies and solutions to these challenges and the path forward for providing patient care.

Shelli Laux, MBA, RHIA, CTR, CCRP, WellSpan Health, shares an overview of effective practices for virtual tumor boards, methods for ensuring attendance and participation, and insights into post-pandemic sustainability. (May 8, 2020)

ACCC and the American Society of Clinical Oncology (ASCO) share how the COVID-19 pandemic presents a unique opportunity to better understand the effects of a disease outbreak on the delivery of high-quality cancer care and research. (June 12, 2020)

How has participation in APMs changed since the onset of the COVID-19 pandemic? How can oncology practices benefit from enrollment and potential future models (i.e., OCM, OCF, RO Model etc.)? These questions and more will be covered by our speakers!

Multiple studies have shown that integrating remote symptom monitoring into cancer care using patient-reported outcomes (PRO) favorably impacts quality of life, healthcare utilization, and overall survival in patients with cancer. However patient adherence with remote PROs outside of a clinical trial is widely variable. With the integration of technology into cancer care and the rapid adoption …